We have located links that may give you full text access.
Comparative Study
Journal Article
Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
American Journal of Surgery 2009 October
BACKGROUND: The aim of this study was to investigate the clinical characteristics associated with invasive lobular cancer (ILC) and mixed invasive ductal cancer (IDC) and ILC compared with IDC.
METHODS: From 1996 to 2006, 4,336 patients with IDC, ILC, and mixed breast cancers were identified. Clinical variables were compared using chi(2) and Fisher's exact tests. Kaplan-Meier survival curves were constructed.
RESULTS: Patients included 3,595 (83%) with IDC, 480 (11%) with ILC, and 261 (6%) with mixed cancers. Patients with ILC and mixed cancers were more likely to have low-grade and estrogen-positive and progesterone-positive tumors but were diagnosed at higher stages of disease compared with patients with IDC (P < .05 for each). Patients with IDC had the poorest 5-year (80%) and 10-year (61%) survival compared with patients with ILC (87% and 68%) and mixed (84% and 69%) cancers (P = .029).
CONCLUSIONS: Although patients with ILC and "mixed" cancers are diagnosed with more advanced disease, their survival is superior to patients with IDC.
METHODS: From 1996 to 2006, 4,336 patients with IDC, ILC, and mixed breast cancers were identified. Clinical variables were compared using chi(2) and Fisher's exact tests. Kaplan-Meier survival curves were constructed.
RESULTS: Patients included 3,595 (83%) with IDC, 480 (11%) with ILC, and 261 (6%) with mixed cancers. Patients with ILC and mixed cancers were more likely to have low-grade and estrogen-positive and progesterone-positive tumors but were diagnosed at higher stages of disease compared with patients with IDC (P < .05 for each). Patients with IDC had the poorest 5-year (80%) and 10-year (61%) survival compared with patients with ILC (87% and 68%) and mixed (84% and 69%) cancers (P = .029).
CONCLUSIONS: Although patients with ILC and "mixed" cancers are diagnosed with more advanced disease, their survival is superior to patients with IDC.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app